health
February 23, 2026
Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday.
TL;DR
- Gilead Sciences will acquire Arcellx for up to $7.8 billion, its largest deal since 2020.
- The acquisition aims to strengthen Gilead's cancer treatment pipeline.
- The deal includes anito-cel, an experimental CAR-T therapy for multiple myeloma, co-developed with Gilead's Kite Pharma unit.
- Analysts predict anito-cel could become a multi-billion dollar product for Gilead.
- Anito-cel is currently under FDA review for fourth-line treatment, with a decision expected by December 23.
- Gilead will also gain Arcellx's early-stage treatments for acute myeloid leukemia and generalized myasthenia gravis.
- The deal is expected to close in the second quarter of 2026 and may be accretive to earnings per share from 2028.
- Gilead is paying a premium of 79% to Arcellx's last closing stock price.
Continue reading the original article